Assessment of Opioid-Prescribing Practices in Breast Augmentation: Future Directions for Prescribing Guidelines.

Annals of plastic surgery 2021 Vol.86(1) p. 11-18

Crystal DT, Cuccolo NG, Plewinski MJ, Ibrahim AMS, Sinkin JC, Lin SJ, Agag RL, Lee BT

관련 도메인

Abstract

[BACKGROUND] The United States (US) is in the mid of an opioid epidemic propagated, in part, by prescription opioids. With excess overprescribing documented in a variety of surgical procedures, several societies have recommended opioid-prescribing guidelines. Considering the scope and postoperative pain associated with aesthetic plastic surgery procedures, earnest evaluation into opioid-prescribing practices for breast augmentation was conducted.

[METHODS] Members of the American Society for Aesthetic Plastic Surgery were electronically surveyed on their opioid-prescribing patterns. The survey was distributed to 1709 plastic surgeons. Descriptive statistics were collated into percentages, deviations, and morphine milligram equivalents (MMEs), when appropriate.

[RESULTS] Two hundred twenty-nine American Society for Aesthetic Plastic Surgery members (13.4%) provided responses. A total of 91.2% of respondents prescribe opioids to patients undergoing breast augmentation. The most commonly prescribed agents included oxycodone/acetaminophen (Percocet, 47.0%) and hydrocodone/acetaminophen (Vicodin, 38.3%). On average, 165.3 ± 81.7 MMEs were dispensed (range, 25.0-600.0 MMEs; number tablets, 5-60). Prescribers felt that a lack of phone-in prescribing (52.4%) and the ease of preemptively prescribing opioids (52.4%) propagate opioid overprescribing. A total of 61.3% of respondents reported that they are or may be in favor of developing plastic surgery societal guidelines related to opioid prescribing. These respondents indicated support for guidelines on opioid-sparing pain management strategies (74.2%) and guidelines identifying the type (54.7%), duration of use (69.5%), and number of opioid tablets (61.7%) necessary for procedures.

[CONCLUSIONS] Considerable variability exists among prescribing patterns after breast augmentation. Societal guidelines aimed at providers and patients may serve a future role in opioid prescribing.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
시술 breast augmentation 유방성형술 dict 4
해부 breast 유방 dict 4
약물 morphine C0026549
morphine
scispacy 1
약물 oxycodone/acetaminophen C0717368
acetaminophen / oxycodone
scispacy 1
약물 Percocet C0086787
Percocet
scispacy 1
약물 hydrocodone/acetaminophen C0717367
acetaminophen / hydrocodone
scispacy 1
약물 Vicodin C0483514
Vicodin
scispacy 1
약물 [BACKGROUND] scispacy 1
약물 opioids scispacy 1
약물 [CONCLUSIONS] Considerable scispacy 1
질환 postoperative pain C0030201
Pain, Postoperative
scispacy 1
질환 pain C0030193
Pain
scispacy 1
질환 MMEs → milligram equivalents scispacy 1
질환 tablets scispacy 1
기타 opioids scispacy 1
기타 patients scispacy 1
기타 MMEs → milligram equivalents scispacy 1
기타 opioid tablets scispacy 1

MeSH Terms

Analgesics, Opioid; Humans; Mammaplasty; Pain Management; Postoperative Pain; Practice Patterns, Physicians'; United States

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문